Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Caitlin E. Cox

August 30, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Daily News

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

L.A. McKeown

March 27, 2023

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

L.A. McKeown

October 09, 2020

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

Dapagliflozin Boosts Health Status Across LVEF Range

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content